JP2024540691A - リン（ｖ）および薬物部分を含むコンジュゲート - Google Patents

リン（ｖ）および薬物部分を含むコンジュゲート Download PDF

Info

Publication number
JP2024540691A
JP2024540691A JP2024549576A JP2024549576A JP2024540691A JP 2024540691 A JP2024540691 A JP 2024540691A JP 2024549576 A JP2024549576 A JP 2024549576A JP 2024549576 A JP2024549576 A JP 2024549576A JP 2024540691 A JP2024540691 A JP 2024540691A
Authority
JP
Japan
Prior art keywords
unit
alkyl
conjugate
optionally substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549576A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023083900A5 (https=
JP2024540691A5 (https=
Inventor
クリスティアン ハッケンベルガー
フィリップ オホトロプ
ジャハジエル ジャーゼラー
ポール マヒュイ
ドミニク シューマッハー
ヨナス ヘルマ－スメッツ
イザベル マイ
マーク－アンドレ キャスパー
Original Assignee
テューブリス ゲーエムベーハー
フォルシュングスフェアバント ベルリン エー．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テューブリス ゲーエムベーハー, フォルシュングスフェアバント ベルリン エー．ベー． filed Critical テューブリス ゲーエムベーハー
Publication of JP2024540691A publication Critical patent/JP2024540691A/ja
Publication of JPWO2023083900A5 publication Critical patent/JPWO2023083900A5/ja
Publication of JP2024540691A5 publication Critical patent/JP2024540691A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4476—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024549576A 2021-11-09 2022-11-09 リン（ｖ）および薬物部分を含むコンジュゲート Pending JP2024540691A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21207195 2021-11-09
EP21207195.5 2021-11-09
PCT/EP2022/081345 WO2023083900A1 (en) 2021-11-09 2022-11-09 Conjugates comprising a phosphorus (v) and a drug moiety

Publications (3)

Publication Number Publication Date
JP2024540691A true JP2024540691A (ja) 2024-10-31
JPWO2023083900A5 JPWO2023083900A5 (https=) 2025-11-17
JP2024540691A5 JP2024540691A5 (https=) 2025-11-17

Family

ID=78592631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549576A Pending JP2024540691A (ja) 2021-11-09 2022-11-09 リン（ｖ）および薬物部分を含むコンジュゲート

Country Status (15)

Country Link
US (2) US20230330258A1 (https=)
EP (1) EP4429708A1 (https=)
JP (1) JP2024540691A (https=)
KR (1) KR20240100413A (https=)
CN (1) CN118302197A (https=)
AU (1) AU2022385379A1 (https=)
CA (1) CA3237371A1 (https=)
CL (1) CL2024001372A1 (https=)
CO (1) CO2024005877A2 (https=)
DE (1) DE22817174T1 (https=)
ES (1) ES2999335T1 (https=)
IL (1) IL312675A (https=)
MX (1) MX2024005546A (https=)
PE (1) PE20242107A1 (https=)
WO (1) WO2023083900A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024133845A1 (en) * 2022-12-22 2024-06-27 Tubulis Gmbh Conjugates comprising a phosphorus(v) moiety and a drug
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025046090A1 (en) 2023-09-01 2025-03-06 Tubulis Gmbh Methods of preparing phosphonamidate compounds
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
EP4658320A1 (en) 2024-02-27 2025-12-10 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
EP1731174A3 (en) 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
KR20200058590A (ko) 2008-04-30 2020-05-27 이뮤노젠 아이엔씨 가교제 및 그 용도
ES2826398T3 (es) 2013-10-15 2021-05-18 Seagen Inc Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
AU2017320913B2 (en) 2016-09-01 2024-08-15 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
JP7429191B2 (ja) 2018-03-07 2024-02-07 フォルシュングスフェアバント ベルリン エー．ベー． アルケンホスホノチオレートまたはアルキンホスホノチオレートおよびアルケンホスホネートまたはアルキンホスホネートとの化学選択的チオールコンジュゲーション
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物

Also Published As

Publication number Publication date
PE20242107A1 (es) 2024-10-28
CA3237371A1 (en) 2023-05-19
AU2022385379A1 (en) 2024-06-20
WO2023083900A1 (en) 2023-05-19
MX2024005546A (es) 2024-07-10
CO2024005877A2 (es) 2024-07-08
CL2024001372A1 (es) 2024-10-25
EP4429708A1 (en) 2024-09-18
US20230330258A1 (en) 2023-10-19
ES2999335T1 (en) 2025-02-25
KR20240100413A (ko) 2024-07-01
US20250281634A1 (en) 2025-09-11
CN118302197A (zh) 2024-07-05
IL312675A (en) 2024-07-01
DE22817174T1 (de) 2024-12-12

Similar Documents

Publication Publication Date Title
JP7556086B2 (ja) エリブリンをベースとする抗体－薬物コンジュゲート及び使用方法
US20250281634A1 (en) Conjugates comprising a phosphorus (v) and a drug moiety
KR102923527B1 (ko) 생체활성 분자 접합체, 이의 제조 방법 및 용도
KR102215954B1 (ko) 튜부리신 화합물, 그의 제조 및 사용 방법
JP2024540692A (ja) リン（ｖ）およびカンプトテシン部分を含むコンジュゲート
CN111542344A (zh) 包含单分子量聚肌氨酸的配体-药物-缀合物
JP2016050204A (ja) 抗体薬物コンジュゲートと共に使用する安定性調節用リンカー
EP3856258B1 (en) Sulfomaleimide-based linkers and corresponding conjugates
US20240269313A1 (en) Conjugates comprising a phosphorus(v) moiety and a drug
EA052263B1 (ru) Конъюгаты, содержащие фрагмент с фосфором (v) и фрагмент лекарственного средства
EA051319B1 (ru) Конъюгаты, содержащие фрагмент с фосфором (v) и фрагмент камптотецина
WO2026018064A1 (en) Multispecific multi-drug antibody-drug conjugates
HK1212209B (en) Tubulysin compounds, methods of making and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251107